Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TILTS: TILs in Advanced SWI/SNF-Altered Solid Tumors
2023-504632-17-00Phase 2Completed
- Sponsor
- Bellvitge Institute for Biomedical Research
- Start
- Sep 2023
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous tumor-infiltrating lymphocytes in Nonhematologic neoplasms, epithelioid sarcoma (ES), malignant rhabdoid tumor (MRT) and 7 more, sponsored by Bellvitge Institute for Biomedical Research. Primary endpoint: Objective response rate (ORR) per RECIST v1.1 by investigator. Started Sep 2023; status: completed.
02
Drugs
autologous tumor-infiltrating lymphocytes
03
Conditions
Nonhematologic neoplasmsepithelioid sarcoma (ES)malignant rhabdoid tumor (MRT)Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT)Kidney medullary carcinoma (RMC)
Beyond the preview
Go deeper on 2023-504632-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504632-17-00.